Financial Results, Community Service, Dividends, and Stockholder Meetings for Merger Agreements - Research Report on Tyson, Hormel, Flowers Foods, Smithfield, and Leucadia
Editor Note: For more information about this release, please scroll to bottom
NEW YORK, August 27, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Tyson Foods Inc. (NYSE: TSN), Hormel Foods Corp. (NYSE: HRL), Flowers Foods, Inc. (NYSE: FLO), Smithfield Foods Inc. (NYSE: SFD), and Leucadia National Corp. (NYSE: LUK). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Tyson Foods Inc. Research Report
On August 19, 2013, Tyson Foods Inc. (Tyson) announced that it will donate Meals through "Be a Hunger Hero" campaign, which has been created through a partnership between Tyson Foods, the Tyson Foundation, Champions for Kids and Sam's Club, and aims to fight childhood hunger by providing four ounces of protein for each meal, to families in need. According to Tyson, protein for up to 308,000 meals will be provided by the Company to families across America for every five-pound bag of Tyson chicken nuggets purchased at Sam's Club stores from August 15 to September 1, 2013. The Full Research Report on Tyson Foods Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/4516_TSN]
Hormel Foods Corp. Research Report
On August 22, 2013, Hormel Foods Inc. (Hormel Foods) released its Q3 FY 2013 (period ended July 28, 2013) financial results. The Company reported sales of $2.2 billion, representing a growth of 7.5% YoY. Net earnings increased 2.2% YoY to $113.6 million, and diluted EPS was up 2.4% YoY to $0.42. Jeffrey M. Ettinger, Chairman of the Board, President and CEO of the Company said, "We had a solid quarter, with all five segments reporting increased sales over last year. We also generated improved earnings, with four of five segments posting increased operating profits. Earnings per share of $0.42 for the third quarter was in line with our expectations and keeps us on pace with our full year adjusted guidance range." The Company reaffirmed its full-year FY 2013 EPS guidance in the range of $1.88 to $1.96. The Full Research Report on Hormel Foods Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/d79d_HRL]
Flowers Foods, Inc. Research Report
On August 16, 2013, Flowers Foods, Inc. (Flowers Foods) announced that its Board of Directors has declared a quarterly dividend of $0.11 per share, payable on September 13, 2013 to shareholders of record as on August 30, 2013. The Company informed that with this dividend announcement, the annual dividend rate is renewed to $0.45. The dividend is The Full Research Report on Flowers Foods, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/f82c_FLO]
Smithfield Foods Inc. Research Report
On August 20, 2013, Smithfield Foods Inc. (Smithfield) announced the filing of its definitive proxy statement with the Securities and Exchange Commission (SEC) in relation with its previously announced definitive merger agreement with Shuanghui International Holdings Limited. The Company informed that a special meeting of its shareholders to approve the merger will be held on September 24, 2013, at 9:00 a.m. ET., and as per the terms of the agreement, each outstanding share of Smithfield common stock would be converted into the right to receive $34 in cash. Smithfield expects the transaction to close in H2 2013 subject to certain conditions, including, approval by Smithfield's shareholders, the receipt of approval under certain specified foreign merger clearance laws, review by the Committee on Foreign Investment in the United States (CFIUS) and other customary closing conditions. The Full Research Report on Smithfield Foods Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/3f6f_SFD]
Leucadia National Corp. Research Report
On August 6, 2013, Leucadia National Corp. (Leucadia) released its Q2 2013 unaudited financial results. The Company reported net revenues of $2.7 billion, compared to $1.7 billion in Q2 2012. Net income attributable to Leucadia common shareholders was $52.6 million or $0.14 per diluted common share, compared to net loss of $197.3 million or $0.81 per diluted common share in Q2 2012. Leucadia stated that the reported results reflect the inclusion of the operations of Jefferies Group LLC and its subsidiaries commencing with Q2 2013. The Full Research Report on Leucadia National Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/1fd1_LUK]
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
SOURCE Analysts' Corner
More by this Source
Global Cell Therapy - Technologies, Markets and Companies
Jan 16, 2014, 14:00 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.